Trial Profile
A single ascending dose study evaluating the safety and tolerability of POL6014 in individuals with cystic fibrosis
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 16 Sep 2019
Price :
$35
*
At a glance
- Drugs Lonodelestat (Primary)
- Indications Cystic fibrosis
- Focus Adverse reactions
- 16 Sep 2019 Results published in the journal of Cystic Fibrosis
- 10 Sep 2019 Results published in the Santhera Pharmaceuticals Media Release
- 24 Oct 2018 Status changed from recruiting to completed, according to a Santhera Pharmaceuticals media release.